Strategic IP leverage Strong patent portfolio and trade secrets create defensible technology positioning, enabling targeted partnerships with larger orthopedic and spine implant players to co-develop or license expanded applications.

FDA cleared core Having FDA 510(k) clearance for both the 3D printed resorbable scaffolds and the Affinity coating signals regulatory readiness and enables risk-mitigated conversations with hospital systems and distributors seeking compliant, innovative solutions.

Proven customization Capability to produce patient-specific, load-bearing, resorbable implants via 3D printing opens opportunities with trauma centers and specialty clinics seeking personalized bone regeneration solutions, including collaborations with surgeons for pilots.

Manufacturing readiness Independent, FDA-compliant manufacturing with a certified cleanroom supports scalable production, appealing to distributors and OEMs needing reliable, compliant supply for commercial adoption.

Strategic exits & upside Past asset sale to DePuy Synthes demonstrates market validation and potential for strategic partnerships or acquisition, suggesting approaches focused on tier-one orthopedic players for co-marketing, asset re-acquisition, or joint development.